This article was originally published in The Gray Sheet
Intravascular beta radiation device premarket approval application is submitted to FDA to treat in-stent restenosis and will receive expedited review by the agency, the firm announces April 17. The PMA is largely based on results of the START (Stents and Radiation Therapy) trial (1"The Gray Sheet" March 20, p. 12)
You may also be interested in...
Novoste Corp. appears poised for a smooth path to FDA approval for the BetaCath beta radiation system, given the 0% incidence of late-stent thrombosis in treating patients for in-stent restenosis.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.